Browse drugs

…ctegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) vs. dolutegravir (DTG)-based single tablet regimens (STR) on treatment failure-r…

… HCV-coinfection, no significant differences were found between DTG and TAF group as regards weight, BMI and lipid profile (see tab…

…Objective Buprenorphine is an atypical opioid with analgesic efficacy and a more favora…

…ential drug interactions were analysed between anticonvulsants (phenytoin, valproate, levetiracetam, phenobarbital, lacosamide, brivarace…

…ed in 81% (N=13) of treatments: 2 atogepant, 1 erenumab, and 10 fremanezumab. A mean of 11 MMDs and 52 HIT6 score were recorded at beginning…

…elial growth factor (anti-VEGF) agents, such as aflibercept and ranibizumab, are widely used. Although generally safe, they carry a risk of…

…rbazepine, phenobarbital, phenytoin, topiramate, valproate, and zonisamide. The reference group consisted of pregnant patients with diagno…

…rogeneity across regions. Polypharmacy was associated with PIP, PIM and PDDI, while hypertension showed association with PIP. Despi…

…demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clini…

… (r/rMM). Two BCMA-targeted CAR T cell therapies, cilta-cel and ide-cel, have received FDA approval and have demonstrated deep initial …

…, 94 de novo lesions treated, with 76.6% (lesions=72) receiving Paclitaxel. Mean age 66.8 years (SD 11.53); 86.5% male. Obesity (BMI >30) …

… Athanassiou L, Kostoglou-Athanassiou I, Koutsilieris M, et al. Vitamin D and autoimmune rheumatic diseases. Biomolecules. 2023;13:709 [I…